ANIK Anika Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ANIK

Price (delayed)

$14.81

Market cap

$197.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.79

Enterprise value

$179.83M

?
Relative Growth: Rel. Growth: 30
Relative Strength: Rel. Strength: 75
Relative Valuation: Rel. Valuation: 23
Relative Profitability: Rel. Profitability: 42

Anika Therapeutics, Inc. is a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care. Anika Therapeutics partners with clinicians to understand what they need ...

Highlights
The net income has surged by 81% year-on-year
The revenue has grown by 3.1% from the previous quarter
The company's EPS has surged by 80% YoY but it fell by 3.9% QoQ
The company's gross profit rose by 7% QoQ but it fell by 5% YoY
Anika Therapeutics's quick ratio has decreased by 24% YoY and by 14% from the previous quarter
ANIK's equity is down by 10% year-on-year and by 7% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.anikatherapeutics.com
Peers: MDT SYK STAA JNJ

Key stats

What are the main financial stats of ANIK

ANIK stock price

How has the Anika Therapeutics stock price performed over time
Intraday
2.78%
1 week
-0.6%
1 month
1.79%
1 year
27.12%
YTD
54.11%
QTD
2.14%

Financial performance

How have Anika Therapeutics's revenue and profit performed over time
Revenue
$116.26M
Gross profit
$68.12M
Operating income
-$12.26M
Net income
-$11.06M
Gross margin
58.6%
Net margin
-9.5%
The net income has surged by 81% year-on-year
Anika Therapeutics's net margin has surged by 80% YoY
Anika Therapeutics's operating income has plunged by 78% YoY and by 11% from the previous quarter
Anika Therapeutics's operating margin has plunged by 78% YoY and by 7% from the previous quarter

Price vs fundamentals

How does ANIK's price correlate with its fundamentals

Growth

What is Anika Therapeutics's growth rate over time

Valuation

What is Anika Therapeutics stock price valuation
ANIK P/E details
P/E
N/A
P/B
1.48
P/S
1.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.55
The company's EPS has surged by 80% YoY but it fell by 3.9% QoQ
ANIK's price to book (P/B) is 31% more than its last 4 quarters average of 1.1 but 4% less than its 5-year quarterly average of 1.5
ANIK's equity is down by 10% year-on-year and by 7% since the previous quarter
ANIK's P/S is 40% below its 5-year quarterly average of 2.8 but 20% above its last 4 quarters average of 1.4
The revenue has grown by 3.1% from the previous quarter

Efficiency

How efficient is Anika Therapeutics business performance
The company's return on sales has surged by 80% YoY and by 2.2% QoQ
Anika Therapeutics's ROE has soared by 77% YoY but it has decreased by 4.1% from the previous quarter
The return on assets has surged by 77% year-on-year but it has declined by 3.5% since the previous quarter
The ROIC has soared by 76% year-on-year

Dividends

What is ANIK's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ANIK.

Financial health

How did Anika Therapeutics financials performed over time
Anika Therapeutics's quick ratio has decreased by 24% YoY and by 14% from the previous quarter
Anika Therapeutics's current ratio has decreased by 22% YoY and by 6% from the previous quarter
Anika Therapeutics's debt is 82% lower than its equity
The debt to equity is up by 13% year-on-year and by 6% since the previous quarter
ANIK's equity is down by 10% year-on-year and by 7% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.